Home › Digestive Diseases › Arkansas › Little Rock
Digestive Diseases clinical trials in Little Rock, AR
4 studies for Digestive Diseases are looking for participants at sites in and around Little Rock (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 2
- Applied Research Center of Arkansas, Little Rock
- Preferred Research Partners, Little Rock
Product Surveillance Registry
RecruitingObservational study
- Little Rock, Little Rock
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
- 89bio Clinical Study Site, Little Rock
- 89bio Clinical Study Site, North Little Rock · 2 mi away
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
- 89bio Clinical Study Site, Little Rock
- 89bio Clinical Study Site, North Little Rock · 2 mi away
About Digestive Diseases
Learn about digestive disorders and how your gastrointestinal (GI) system works. Find out what tests you need in case you sense a problem.
More about Digestive Diseases on MedlinePlus
Digestive Diseases trials in other cities
- Houston, TX8 studies
- New York City, NY8 studies
- Chicago, IL8 studies
- Washington, DC6 studies
- Boston, MA6 studies
- Durham, NC6 studies
- San Diego, CA6 studies
- Rochester, MN5 studies
- San Antonio, TX5 studies
- St. Louis, MO5 studies
- Cincinnati, OH5 studies
- Chandler, AZ5 studies
Other studies in Little Rock
- Schizophrenia19 studies
- Cancer (all types)15 studies
- Major Depressive Disorder14 studies
- Acute Myeloid Leukemia13 studies
- Non-Small Cell Lung Cancer13 studies
- Endometrial Cancer11 studies
- Obesity11 studies
- Depression10 studies
- Type 2 Diabetes10 studies
- Cardiovascular Disease9 studies
- Bladder Cancer9 studies
- Lung Cancer9 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.